GAS5 and cancer: While mTOR inhibitors increase GAS5 lncRNA levels in hormone-sensitive breast cancer cells, they are ineffective in triple-negative breast cancer (TNBC) cells and other hormone-independent cancer cells [14, 20], so that alternative, mTOR inhibitor-independent, approaches are required to activate this key pathway across a broad range of cancer subtypes.